Icotinib

• UNSPSC Description:

  Icotinib (BPI-2009) is a potent and specific EGFR inhibitor with an IC50 of 5 nM; also inhibits mutant EGFRL858R, EGFRL858R/T790M, EGFRT790M and EGFRL861Q. Icotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

• Target Antigen:

  EGFR

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/icotinib.html

• Solubility:

  DMSO : ≥ 155 mg/mL

• Smiles:

  C#CC1=CC(NC2=C(C=C(OCCOCCOCCO3)C3=C4)C4=NC=N2)=CC=C1

• Molecular Weight:

  391.42

• References & Citations:

  [1]Tan F, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 2012 May;76(2):177-82.Cell Rep Med. 2023 Jan 10;100911.|Clin Chim Acta. 2022 Jan 6;S0009-8981(21)00457-5.|Eur J Pharmacol. 2019 May 5;850:141-149.|J Pharmaceut Biomed. 2023 Jan 26.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Biochem Pharmacol. 2016 Dec 1;121:67-77. |Mol Syst Biol. 2023 Dec 18.|Science. 2017 Dec 1;358(6367):eaan4368.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Launched

• CAS Number:

  610798-31-7